KRAS and colorectal cancer: By contrast, MSI-positive colorectal cancers with KRAS (HR 0·28 [95% CI 0·09–0·89]; p=0·028) or BRAF (0·55 [0·35–0·90]; p=0·017) mutations were associated with a significantly better prognosis than the triple negatives (table 4), although the difference was not significant compared with MSI-positive colorectal cancers without KRAS or BRAF mutations.